nct_id,phase,start_date,enrollment_type,drug,official_title,brief_title,American Indian/ Alaska Native,Asian/ Asian Heritage,Black/ Black Heritage,Hawaiian/ Other Pacific Islander,Hispanic/ Latino,Middle Eastern,Mixed,Other,Unknown or Not Reported,White/ White Heritage
NCT00054665,Phase 2,28/02/2003,Actual,bortezomib,PS-341 and PS-341 + Epoch Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas,PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma,0,0,4,0,1,,0,,2,93
NCT00062439,Phase 2,31/07/2003,Actual,docetaxel,"A Phase II Trial of Induction Chemoradiotherapy With Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)",S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors,1,3,0,0,,,0,,0,40
NCT00065182,Phase 2,14/08/2003,Actual,docetaxel,WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,0,12,46,0,,,0,,6,734
NCT00089609,Phase 2,19/04/2005,Actual,docetaxel,"A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer","Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer",0,0,22,0,8,,0,,2,260
NCT00103376,Phase 2,31/10/2004,Actual,bortezomib,VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer,Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer,0,0,6,0,,,0,,0,40
NCT00108069,Phase 2,30/04/2005,Actual,bortezomib,A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas,Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors,0,2,0,0,2,,0,,8,156
NCT00109005,Phase 2,30/04/2005,Actual,lenalidomide,"A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma",Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma,0,2,0,0,0,,0,,0,66
NCT00114738,Phase 2,15/06/2005,Actual,bortezomib,Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,0,2,2,0,4,,0,,3,95
NCT00116753,Phase 2,31/01/2005,Actual,degarelix,"An Open-label Multi-center, Randomized Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer",A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer,12,24,192,6,,,0,,0,2448
NCT00116779,Phase 2,29/02/2004,Actual,degarelix,"An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles",A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer,0,4,36,0,,,0,,0,214
NCT00117286,Phase 2/Phase 3,31/03/2005,Actual,degarelix,"An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer",Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer,0,2,14,0,,,0,,0,98
NCT00129376,Phase 2,28/02/2003,Actual,docetaxel,Multicenter Phase II Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel (T) as Neoadjuvant Treatment for Operable Stage II and IIIA Breast Cancer Patients,Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients,0,0,0,0,,,0,,0,63
NCT00148122,Phase 2,30/11/2002,Actual,docetaxel,"A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients With Metastatic or Advanced, Locally, Recurrent Head and Neck Cancer",A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer,0,0,0,0,,,0,,2,36
NCT00148317,Phase 2,30/06/2005,Actual,bortezomib,"A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients","Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma",0,3,4,0,4,,0,,5,60
NCT00179309,Phase 2,30/09/2005,Actual,docetaxel,A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer,Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer,0,6,20,0,6,,0,,0,160
NCT00182637,Phase 2,31/07/2004,Actual,bortezomib,A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL),Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma,0,0,1,0,,,0,,0,4
NCT00184028,Phase 2,30/09/2004,Actual,docetaxel,Phase II Trial of Taxotere and Oxaliplatin Combination Chemotherapy in Squamous Cell Carcinoma of the Head and Neck,Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck,0,2,2,0,2,,0,,2,16
NCT00201825,Phase 2,31/12/2004,Actual,docetaxel,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,0,0,4,0,,,0,,0,25
NCT00215683,Phase 2/Phase 3,28/02/2005,Actual,degarelix,"An Open-Label, Multi-Centre, Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer.",An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer,0,2,6,0,,,0,,0,266
NCT00217672,Phase 2,31/05/2005,Actual,docetaxel,A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer,0,4,9,0,8,,0,,8,105
NCT00225420,Phase 1/Phase 2,31/08/2005,Actual,docetaxel,"A Phase I/II Study of Concurrent Weekly Docetaxel (Taxotere®), Androgen Ablation, and Adaptive External Beam Radiotherapy for Localized High-Risk Adenocarcinoma of the Prostate","Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer",0,0,4,0,,,0,,0,14
NCT00238238,Phase 2,31/03/2006,Actual,lenalidomide,"A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory",Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab,0,2,8,2,,,0,,8,162
NCT00268892,Phase 2/Phase 3,31/01/2006,Actual,degarelix,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients With Prostate Cancer",Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer,6,12,66,0,,,0,,0,1584
NCT00271505,Phase 2,05/12/2005,Actual,docetaxel,A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer,Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer,0,4,2,0,2,,0,,0,72
NCT00276614,Phase 2,30/04/2006,Actual,bortezomib,A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients,Bortezomib in Treating Patients With Metastatic Kidney Cancer,0,0,0,0,,,0,,0,4
NCT00280735,Phase 2,31/05/2004,Actual,docetaxel,Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer,Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC,,1,7,,4,,,,4,128
NCT00281840,Phase 2,30/09/2005,Actual,docetaxel,A Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck,"Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",0,0,0,0,0,,0,,2,58
NCT00287287,Phase 2,28/02/2006,Actual,lenalidomide,Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas,REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas,0,2,0,0,0,,0,,0,48
NCT00290706,Phase 1/Phase 2,07/04/2006,Actual,bortezomib,A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma,A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma,2,2,10,0,6,,0,,0,108
NCT00295750,Phase 3,28/02/2006,Actual,degarelix,"An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy",The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer,236,8,152,0,,,0,,0,2044
NCT00295932,Phase 1/Phase 2,13/12/2005,Actual,bortezomib,"A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)","Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",0,10,8,0,,,0,,4,136
NCT00310037,Phase 2,30/06/2006,Actual,bortezomib,A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma,"Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma",0,0,6,0,2,,0,,34,366
NCT00352001,Phase 1/Phase 2,31/05/2006,Actual,lenalidomide,A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS),Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes,0,0,1,0,2,,0,,7,64
NCT00352794,Phase 2,07/07/2006,Actual,lenalidomide,Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF),Lenalidomide for Patients With Myelofibrosis (MF),0,1,0,0,,,0,,1,38
NCT00369707,Phase 2,09/08/2006,Actual,bortezomib,A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma,Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL,0,0,4,1,3,,0,,0,76
NCT00376961,Phase 2,31/08/2006,Actual,bortezomib,A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade®) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma,"S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",0,1,2,1,1,,0,,13,112
NCT00390429,Phase 1/Phase 2,31/07/2002,Actual,docetaxel,Phase I/II Study of Docetaxel and OSI-774 (Erlotinib) in Solid Tumor Patients With an Emphasis on NSCLC Using Molecular Correlates as Potential Markers of Response,Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,,10,6,,,,,,,146
NCT00439231,Phase 2,28/02/2007,Actual,lenalidomide,A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,0,0,4,0,0,,0,,7,55
NCT00440726,Phase 1/Phase 2,04/08/2006,Actual,bortezomib,A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia,Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL),0,4,0,0,18,,0,,8,94
NCT00441168,Phase 2,31/12/2006,Actual,bortezomib,"A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma","Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma",0,0,0,0,,,0,,0,58
NCT00445692,Phase 2,10/01/2007,Actual,lenalidomide,"Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma","Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma",0,0,2,0,,,0,,1,28
NCT00448760,Phase 2,31/10/2004,Actual,docetaxel,"A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma",Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery,0,0,3,0,7,,0,,0,48
NCT00460031,Phase 2,01/09/2006,Actual,lenalidomide,Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation,Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy,0,0,3,0,0,,0,,2,63
NCT00466921,Phase 2,19/04/2005,Actual,lenalidomide,"Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma",Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome,0,0,6,0,1,,0,,1,58
NCT00468286,Phase 2,31/05/2007,Actual,degarelix,"An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy",Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy,0,4,20,0,,,0,,0,508
NCT00482911,Phase 2,30/04/2007,Actual,lenalidomide,"A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma","Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",0,0,2,0,0,,0,,0,46
NCT00492050,Phase 2,31/08/2006,Actual,bortezomib,Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection,Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia,0,2,3,0,2,,0,,2,65
NCT00500110,Phase 2,30/06/2003,Actual,docetaxel,"Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer","Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer",0,0,4,0,,,0,,0,35
NCT00510718,Phase 1,23/07/2007,Actual,enzalutamide,"A PHASE 1, OPEN-LABEL, DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF MDV3100 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER",A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer,2,0,8,0,10,,0,,2,538
NCT00538733,Phase 2,31/10/2007,Actual,lenalidomide,"A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma","Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma",0,2,0,0,3,,0,,4,43
NCT00538824,Phase 2,31/12/2007,Actual,lenalidomide,"A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma","Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma",0,0,1,0,0,,0,,0,9
NCT00556374,Phase 3,18/12/2006,Actual,denosumab,"A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.",Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy,,24,2,,8,,,,2,6804
NCT00571493,Phase 1/Phase 2,30/04/2006,Actual,bortezomib,"Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma","VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma",,,,,0,,,,0,42
NCT00584012,Phase 1,30/04/2004,Actual,docetaxel,A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer,A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer,0,0,0,0,,,0,,0,9
NCT00619684,Phase 2,29/02/2008,Actual,lenalidomide,A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression,Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant,0,0,1,0,0,,0,,0,35
NCT00632359,Phase 2,29/02/2008,Actual,lenalidomide,A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270,Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease,0,0,0,0,,,0,,1,32
NCT00670358,Phase 1/Phase 2,25/08/2008,Actual,lenalidomide,"Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma","Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma",0,0,2,0,2,,0,,6,542
NCT00679367,Phase 2,31/05/2008,Actual,lenalidomide,"A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis","Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis",0,0,1,0,,,0,,0,15
NCT00695786,Phase 2,10/06/2008,Actual,lenalidomide,A Phase II Study of Revlimid in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Hodgkin's Lymphoma (NHL),Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma,2,4,12,0,28,,0,,102,476
NCT00711243,Phase 1/Phase 2,20/04/2005,Actual,docetaxel,"A Phase I/II Study of Taxotere, Oxaliplatin, and 5- Fluorouracil","Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor",0,16,16,0,8,,0,,14,182
NCT00737529,Phase 2,22/12/2008,Actual,lenalidomide,"A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortezomib","A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The ""EMERGE"" Trial",,3,1,,,,,2,,128
NCT00765245,Phase 2,31/10/2008,Actual,lenalidomide,A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma,Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma,0,0,12,0,4,,4,,32,300
NCT00774345,Phase 3,27/01/2009,Actual,lenalidomide,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)",A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy,0,10,10,2,14,,0,,6,1226
NCT00783367,Phase 2,31/07/2008,Actual,lenalidomide,Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab,"Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",0,0,2,0,4,,0,,0,194
NCT00790842,Phase 1/Phase 2,21/01/2009,Actual,lenalidomide,A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function,Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction,2,0,16,0,0,,0,,4,226
NCT00792077,Phase 2,30/11/2008,Actual,lenalidomide,A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue,A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue,0,0,2,0,1,,0,,1,8
NCT00819156,Phase 2,29/02/2004,Actual,degarelix,"An Open-label, Randomised, Multi-centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months",Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer,0,2,12,0,,,0,,0,360
NCT00831233,Phase 3,30/04/2009,Actual,degarelix,"A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer",Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer,0,0,2,0,,,0,,0,78
NCT00833248,Phase 3,30/04/2009,Actual,degarelix,"A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)",Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer,2,2,36,0,,,0,,0,448
NCT00843882,Phase 3,29/01/2009,Actual,lenalidomide,Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid�) Alone and in Combination With Epoetin Alfa (Procrit�) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,0,10,8,0,10,,0,,50,910
NCT00875667,Phase 2,30/04/2009,Actual,lenalidomide,"A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma",A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL),0,0,0,0,,,0,,26,482
NCT00884273,Phase 3,31/08/2009,Actual,degarelix,"A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration",Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients,0,0,0,0,,,0,,0,358
NCT00884312,Phase 2,09/04/2009,Actual,carfilzomib,"An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols",A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols,,8,22,,10,,,,,160
NCT00890552,Not Applicable,30/04/2009,Actual,lenalidomide,"A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis","A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis",0,1,0,0,2,,0,,3,44
NCT00896532,Phase 2,03/06/2009,Actual,denosumab,"A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density",Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density,,10,6,2,96,,,,,724
NCT00899431,Phase 2,06/05/2009,Actual,lenalidomide,Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294),Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL),0,2,12,0,,,0,,2,60
NCT00926380,Phase 2,30/06/2009,Actual,denosumab,The Denosumab And Teriparatide Administration Study (DATA),"Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis",0,2,6,0,4,,0,,0,364
NCT00928434,Phase 3,31/05/2009,Actual,degarelix,"A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment",A Study of Degarelix in Patients With Prostate Cancer,20,8,316,0,140,,0,,4,2736
NCT00939510,Phase 1/Phase 2,31/07/2005,Actual,lenalidomide,Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer,Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer,0,0,3,0,0,,0,,5,56
NCT00942578,Phase 2,16/07/2009,Actual,lenalidomide,"A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer","A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer",0,2,36,2,2,,0,,0,210
NCT00946920,Phase 3,30/06/2009,Actual,degarelix,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy",A Trial of Degarelix in Patients With Prostate Cancer,140,10,114,2,,,0,,0,1428
NCT00963105,Phase 2,19/10/2009,Actual,lenalidomide,"A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia",Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,,,16,,,,,2,2,188
NCT00966693,Phase 1/Phase 2,25/08/2009,Actual,lenalidomide,"Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma",0,2,36,0,6,,0,,0,212
NCT00974311,Phase 3,30/09/2009,Actual,enzalutamide,"Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy",Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,4,26,94,2,110,,0,,50,4510
NCT00988208,Phase 3,11/11/2009,Actual,lenalidomide,A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC),Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,16,28,92,,,,,,244,1738
NCT01002755,Phase 2,19/01/2010,Actual,lenalidomide,Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL),Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,0,0,3,0,,,0,,1,32
NCT01003769,Phase 1/Phase 2,09/07/2015,Actual,lenalidomide,A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL),Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia,0,0,0,0,0,,0,,1,9
NCT01011894,Phase 2,06/11/2009,Actual,lenalidomide,A Phase II Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age,Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age,0,0,2,0,,,0,,0,24
NCT01021423,Phase 3,01/04/2010,Actual,lenalidomide,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma",A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).,0,0,0,0,,,0,,0,18
NCT01029262,Phase 3,26/01/2010,Actual,lenalidomide,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Compare The Efficacy And Safety of Lenalidomide (Revlimid®) Versus Placebo In Subjects With Transufsion-Dependent Anemia Due to IPSS Low Or Imtermidate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q(31) And Unresponsive Or Refractory To Erthropoiesis-Stimulating Agents",A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q,,28,4,,,,,4,38,404
NCT01034592,Phase 1,30/11/2009,Actual,lenalidomide,A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia,Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia,0,0,0,0,0,,0,,0,4
NCT01038635,Phase 1/Phase 2,31/12/2009,Actual,lenalidomide,Phase I/II Study of the Combination of 5-azacitidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML),5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML),0,0,12,0,8,,0,,16,316
NCT01054144,Phase 2,14/01/2010,Actual,lenalidomide,"Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma",Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma,0,0,2,0,2,,0,,0,50
NCT01057121,Phase 1/Phase 2,27/08/2010,Actual,lenalidomide,A Phase I/II Study of Lenalidomide in Patients With AIDS-Associated Kaposi's Sarcoma,Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma,0,2,12,4,16,,4,,4,110
NCT01057225,Phase 1/Phase 2,31/03/2010,Actual,carfilzomib,"A Phase I/II Trial of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients With Newly Diagnosed Active Multiple Myeloma","Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma",0,1,4,0,,,0,,5,54
NCT01060384,Phase 1/Phase 2,31/03/2010,Actual,lenalidomide,Phase I/II Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma,Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma,,,,,0,,,,0,46
NCT01075321,Phase 1/Phase 2,10/01/2011,Actual,lenalidomide,A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy,Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,0,0,0,0,,,1,,0,54
NCT01076543,Phase 1/Phase 2,15/04/2010,Actual,lenalidomide,Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas,Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,2,6,28,0,,,0,,8,176
NCT01077154,Phase 3,02/06/2010,Actual,denosumab,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)",Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE),2,1408,288,14,494,,,76,,6736
NCT01080391,Phase 3,14/07/2010,Actual,carfilzomib,"A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma","Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",2,,46,,,,8,20,,1508
NCT01080391,Phase 3,14/07/2010,Actual,lenalidomide,"A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma","Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",2,,46,,,,8,20,,1508
NCT01088048,Phase 1,25/03/2010,Actual,lenalidomide,"A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",,22,18,,8,,,2,28,886
NCT01109004,Phase 3,31/05/2010,Actual,lenalidomide,A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (BMT CTN 0702),Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702),,,520,,,,,,228,2284
NCT01121757,Phase 2,30/04/2010,Actual,lenalidomide,A Phase 2 Study Evaluating the Efficacy of Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma,Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma,0,0,0,0,0,,0,,0,36
NCT01123356,Phase 2,31/05/2010,Actual,lenalidomide,Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab,Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab,0,0,4,0,4,,0,,0,34
NCT01125176,Phase 2,30/03/2012,Actual,lenalidomide,A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL,Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL,0,0,0,0,0,,0,,0,28
NCT01155583,Phase 1/Phase 2,30/06/2010,Actual,lenalidomide,A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma,"Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma",0,0,8,0,0,,0,,10,158
NCT01169337,Phase 3,24/01/2011,Actual,lenalidomide,Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma,0,4,74,0,12,,0,,50,764
NCT01178814,Phase 2,31/07/2010,Actual,lenalidomide,A Prospective Trial of Revlimid® in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome,Revlimid in Transfusion Dependent Patients,0,0,3,0,2,,0,,53,56
NCT01197560,Phase 2/Phase 3,02/09/2010,Actual,lenalidomide,"A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),,4,2,,,,,10,40,148
NCT01199575,Phase 2,31/08/2010,Actual,lenalidomide,"A Phase II Trial of Revlimid® and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),0,0,0,0,,,0,,0,30
NCT01208051,Phase 1/Phase 2,09/09/2010,Actual,lenalidomide,Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,2,16,14,0,,,2,,6,206
NCT01216683,Phase 2,13/12/2010,Actual,lenalidomide,A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",2,10,22,0,18,,0,,26,954
NCT01218555,Phase 1,09/09/2010,Actual,lenalidomide,Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma,Study of Everolimus (RAD001) in Combination With Lenalidomide,0,4,8,0,3,,0,,1,72
NCT01221727,Phase 1,30/11/2010,Actual,denosumab,"The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam, a Cytochrome P450 3A4/P-gp (CYP3A4) Substrate, in Postmenopausal Osteoporotic Women",The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam,0,4,4,0,22,,0,,0,78
NCT01239797,Phase 3,20/06/2011,Actual,lenalidomide,"Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)",Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma,0,128,46,2,12,,,26,1160,1210
NCT01241786,Phase 2,31/07/2010,Actual,lenalidomide,"A Phase II, Single Arm Study Examining the Combination of Revlimid (Lenalidomide) and Vidaza (Azacitidine) (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)",Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL,0,0,0,0,1,,0,,1,8
NCT01242748,Phase 3,31/10/2010,Actual,degarelix,"An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy",A Degarelix Trial in Patients With Prostate Cancer,110,2,20,0,,,0,,0,444
NCT01246063,Phase 1/Phase 2,14/05/2012,Actual,carfilzomib,"A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma","Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",0,0,18,0,0,,0,,8,134
NCT01288911,Phase 2,22/03/2011,Actual,enzalutamide,"A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer",A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer,,,,,8,,,,,742
NCT01303965,Phase 1/Phase 2,07/02/2011,Actual,lenalidomide,Phase I/II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy With Lenalidomide and Sirolimus in Patients With High-Risk Multiple Myeloma,Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM),0,2,0,0,0,,0,,0,54
NCT01335399,Phase 3,04/08/2011,Actual,lenalidomide,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma","Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma",0,10,58,2,34,,0,,1152,1736
NCT01349569,Phase 2,31/01/2012,Actual,lenalidomide,Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission,Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission,0,1,3,0,,,0,,1,11
NCT01351623,Phase 2,09/05/2011,Actual,carfilzomib,Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma,Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma,0,2,18,0,9,,0,,2,57
NCT01375140,Phase 2,22/09/2011,Actual,lenalidomide,Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis,Ruxolitinib and Lenalidomide for Patients With Myelofibrosis,0,1,3,0,,,0,,0,27
NCT01377389,Phase 2,17/06/2011,Actual,degarelix,A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate Carcinoma,Ipilimumab + Androgen Depravation Therapy in Prostate Cancer,0,0,1,0,,,0,,0,29
NCT01383928,Phase 1/Phase 2,31/10/2011,Actual,lenalidomide,"An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment",Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma,,,16,,2,,,2,4,232
NCT01402284,Phase 2,21/07/2011,Actual,carfilzomib,"Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study","Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients",0,2,6,0,0,,0,,0,82
NCT01402284,Phase 2,21/07/2011,Actual,lenalidomide,"Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study","Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients",0,6,18,0,0,,0,,0,246
NCT01419717,Phase 3,22/11/2011,Actual,denosumab,Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer,Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer,,15,6,,28,,,4,1,204
NCT01419795,Phase 2,31/05/2012,Actual,lenalidomide,A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab,"Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",0,0,0,0,0,,0,,6,6
NCT01421186,Phase 1/Phase 2,31/07/2011,Actual,lenalidomide,"A Phase 1/2a, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD 38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma",A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma,0,0,0,0,,,0,,0,182
NCT01442714,Phase 2,31/08/2011,Actual,lenalidomide,Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS) (VIREL2 Trial),Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS,0,1,2,0,,,0,,2,28
NCT01463670,Phase 2,28/10/2011,Actual,lenalidomide,A Phase II Clinical Trial of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance,Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance,0,0,2,0,2,,0,,3,15
NCT01496118,Phase 1/Phase 2,31/12/2011,Actual,carfilzomib,Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma,Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma,0,2,22,0,8,,0,,20,268
NCT01496976,Phase 2,30/03/2012,Actual,lenalidomide,Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial,"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL",0,0,0,0,0,,0,,1,89
NCT01497496,Phase 2,26/01/2012,Actual,lenalidomide,Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial,Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),0,0,0,0,2,,0,,4,52
NCT01522976,Phase 2,01/03/2012,Actual,lenalidomide,A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML),Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia,4,14,18,2,,,0,,18,498
NCT01534052,Phase 2,21/10/2011,Actual,enzalutamide,A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100,A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100,0,0,2,0,0,,0,,3,99
NCT01553149,Phase 2,19/03/2012,Actual,lenalidomide,"A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas","Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma",0,2,10,0,10,,0,,20,258
NCT01559935,Phase 2,31/03/2012,Actual,carfilzomib,"A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma","Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma",0,0,12,0,8,,16,,107,225
NCT01559935,Phase 2,31/03/2012,Actual,lenalidomide,"A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma","Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma",0,0,24,0,16,,32,,214,450
NCT01565928,Phase 1,24/01/2012,Actual,enzalutamide,"A PHASE 1B, OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF ORAL MDV3100 IN COMBINATION WITH DOCETAXEL IN MEN WITH ADVANCED PROSTATE CANCER",Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer,0,0,3,0,0,,0,,0,41
NCT01568866,Phase 3,20/06/2012,Actual,carfilzomib,"A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma",Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,,226,34,4,,,2,,190,1402
NCT01572480,Phase 2,29/05/2012,Actual,carfilzomib,"Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study","Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma",0,1,15,0,2,,0,,1,91
NCT01572480,Phase 2,29/05/2012,Actual,lenalidomide,"Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study","Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma",0,1,15,0,2,,0,,1,91
NCT01575860,Phase 1/Phase 2,30/04/2012,Actual,lenalidomide,Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas,Maintenance Lenalidomide in Lymphoma,0,0,0,0,0,,0,,0,12
NCT01592370,Phase 1/Phase 2,02/08/2012,Actual,daratumumab,Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies,An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma,0,6,52,2,40,,0,,60,1104
NCT01668719,Phase 1/Phase 2,30/11/2012,Actual,lenalidomide,"A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)","S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",0,0,30,0,6,,0,,16,372
NCT01675141,Phase 2,20/08/2012,Actual,lenalidomide,Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study,Lenalidomide Maintenance Therapy for Multiple Myeloma,2,0,2,0,,,1,,1,5
NCT01677858,Phase 1/Phase 2,04/07/2012,Actual,carfilzomib,A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma,A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma,,,,,22,,,,0,210
NCT01696877,Phase 1/Phase 2,18/01/2013,Actual,degarelix,A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy,A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer,0,0,4,0,,,0,,0,54
NCT01704781,Phase 1/Phase 2,30/09/2012,Actual,lenalidomide,A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).,Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART),0,4,2,0,0,,0,,0,138
NCT01706666,Phase 2,07/12/2012,Actual,lenalidomide,A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma,Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant,0,0,2,0,0,,0,,0,10
NCT01731886,Phase 4,30/09/2012,Actual,lenalidomide,A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma,Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma,0,0,20,0,,,2,,12,86
NCT01738594,Phase 1,22/03/2013,Actual,carfilzomib,A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma,Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma,0,0,6,0,0,,0,,0,22
NCT01751451,Phase 2,18/12/2012,Actual,degarelix,"A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",0,0,22,0,2,,0,,14,458
NCT01775930,Phase 2,31/10/2013,Actual,carfilzomib,Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma,Carfilzomib in Refractory Renal Cell Carcinoma (RCC),0,0,0,0,1,,0,,1,16
NCT01782963,Phase 2,31/03/2013,Actual,lenalidomide,"A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma",Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM),,3,2,,,,,3,,42
NCT01794039,Phase 2,31/03/2014,Actual,lenalidomide,Randomized Phase 2 Trial of Retreatment With Pomalidomide or Lenalidomide With Dexamethasone for Patients With Relapsed Myeloma,Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide,0,0,0,0,,,0,,0,18
NCT01816971,Phase 2,31/01/2013,Actual,carfilzomib,"Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy","Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",0,2,14,0,,,1,,0,59
NCT01816971,Phase 2,31/01/2013,Actual,lenalidomide,"Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy","Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",0,2,14,0,,,1,,0,59
NCT01818752,Phase 3,08/07/2013,Actual,carfilzomib,"A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",,,,,66,,,,104,1740
NCT01842308,Phase 1/Phase 2,04/06/2013,Actual,carfilzomib,A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL),Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma,,,,,2,,,,6,90
NCT01850524,Phase 3,17/05/2013,Actual,lenalidomide,"A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma",IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma,6,192,48,2,52,,0,,14,2506
NCT01856192,Phase 2,27/08/2013,Actual,lenalidomide,"Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma",Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,0,16,32,0,16,,0,,40,1016
NCT01881789,Phase 1/Phase 2,28/10/2013,Actual,lenalidomide,"Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma","Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma",2,0,2,0,2,,,0,2,76
NCT01891643,Phase 3,30/09/2013,Actual,lenalidomide,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma",PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy),0,0,4,0,0,,0,,36,52
NCT01903811,Phase 2,31/10/2013,Actual,carfilzomib,A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease,"S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma",2,10,38,0,,,2,,6,184
NCT01924169,Phase 2,24/11/2014,Actual,lenalidomide,A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544,Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL),0,0,0,0,0,,0,,0,6
NCT01927627,Phase 2,11/11/2013,Actual,enzalutamide,A Phase 2 Study of Enzalutamide in Patients With High-risk Prostate Cancer Who Have Undergone Local Definitive Therapy With Radical Prostatectomy,Enzalutamide in Patients With High-risk Prostate Cancer,0,0,0,0,0,,0,,0,84
NCT01927718,Not Applicable,31/01/2014,Actual,lenalidomide,A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma,Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT),0,0,4,0,0,,0,,2,14
NCT01938001,Phase 3,21/11/2013,Actual,lenalidomide,"A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma",Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma),,,,,88,,,236,32,1076
NCT01942837,Phase 2,13/09/2013,Actual,enzalutamide,Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing,Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer,0,1,4,0,,,1,,8,51
NCT01946165,Phase 2,31/10/2013,Actual,enzalutamide,A Pre-Operative Study to Assess the Effects of Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-Risk for Recurrence,Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide,0,6,12,0,,,0,,22,96
NCT01949337,Phase 3,22/01/2014,Actual,enzalutamide,"Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,8,56,324,4,,,0,,54,2176
NCT01949532,Phase 1,31/01/2014,Actual,carfilzomib,"An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease",Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease,,,,,2,,,,4,46
NCT01959698,Phase 1,17/04/2014,Actual,carfilzomib,Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma",0,0,0,0,,,0,,0,58
NCT01962792,Phase 1/Phase 2,31/12/2013,Actual,carfilzomib,"A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma","Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma",,,,,20,,,,2,146
NCT01969565,Phase 2,31/08/2013,Actual,carfilzomib,"An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma",Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma,0,1,0,0,0,,0,,0,1
NCT01974765,Phase 2,05/11/2013,Actual,enzalutamide,"A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",0,5,2,0,2,,0,,4,105
NCT01977651,Phase 4,25/09/2013,Actual,enzalutamide,"A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure",A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide,,25,9,1,89,,,4,6,712
NCT01981122,Phase 2,30/09/2013,Actual,enzalutamide,"A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer",A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer,0,0,4,0,,,0,,0,100
NCT01987232,Phase 1/Phase 2,05/11/2013,Actual,carfilzomib,"Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer","Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer",,,,,2,,,2,2,122
NCT02012296,Phase 1/Phase 2,13/12/2013,Actual,enzalutamide,A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC),Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,0,4,38,0,,,0,,10,124
NCT02020941,Phase 2,30/09/2013,Actual,carfilzomib,A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy,Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy,0,0,0,0,,,0,,0,10
NCT02028988,Phase 2,28/02/2014,Actual,enzalutamide,Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study,Enzalutamide + External Beam Rt For Prostate,0,0,5,0,,,1,,8,50
NCT02034552,Phase 2,07/03/2014,Actual,enzalutamide,A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),0,6,20,0,6,,0,,8,232
NCT02036502,Phase 1,14/02/2014,Actual,carfilzomib,A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma,A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),0,2,16,0,26,,0,,26,238
NCT02036502,Phase 1,14/02/2014,Actual,lenalidomide,A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma,A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),0,2,16,0,26,,0,,26,238
NCT02038153,Phase 1/Phase 2,31/12/2013,Actual,lenalidomide,A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML),Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant,,0,2,,1,,,,,0
NCT02042950,Phase 2,14/07/2014,Actual,carfilzomib,A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma,A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma,,,,,1,,,,0,3
NCT02047253,Phase 2,30/04/2014,Actual,carfilzomib,A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors,Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment,0,0,6,0,,,0,,0,22
NCT02057939,Phase 2,30/04/2014,Actual,enzalutamide,Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),0,1,3,0,0,,0,,0,72
NCT02058706,Phase 2,31/05/2014,Actual,enzalutamide,Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer,LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer,0,0,58,0,,,0,,0,84
NCT02064582,Phase 2,31/05/2014,Actual,enzalutamide,"Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",0,0,3,0,0,,0,,0,11
NCT02077166,Phase 1/Phase 2,13/03/2014,Actual,lenalidomide,"A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,,,,20,,,,0,248
NCT02086552,Phase 2,17/01/2014,Actual,lenalidomide,Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma,Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,0,1,0,0,0,,0,,4,51
NCT02090114,Phase 2,25/08/2014,Actual,enzalutamide,A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies,RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study),,,,,4,,,,26,162
NCT02091960,Phase 2,28/08/2014,Actual,enzalutamide,"A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer",0,3,8,1,5,,,1,0,188
NCT02099864,Phase 2,05/02/2014,Actual,enzalutamide,Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment,Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy,1,1,1,0,1,,0,,3,65
NCT02126553,Phase 2,13/11/2014,Actual,lenalidomide,Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission,Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission,0,2,3,0,,,0,,4,20
NCT02135445,Phase 2,30/06/2014,Actual,degarelix,"A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)",Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer,,,,,10,,,,2,194
NCT02135484,Not Applicable,19/09/2014,Actual,radium_223,"An Observation, Open Label Study of Alpharadin (Radium 223) in Patients With Castrate Resistant Prostate Cancer Bone Metastases",Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases,0,1,3,0,1,,0,,7,38
NCT02142049,Phase 1/Phase 2,31/05/2014,Actual,lenalidomide,A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma,Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma,0,4,4,0,0,,0,,10,122
NCT02145403,Phase 1/Phase 2,31/10/2014,Actual,carfilzomib,Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies,Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies,,,,,0,,,,4,98
NCT02159365,Phase 2,08/03/2014,Actual,lenalidomide,A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,0,3,6,0,8,,,4,0,119
NCT02199197,Phase 2,25/06/2014,Actual,enzalutamide,A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer,Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer,0,2,0,0,2,,0,,0,192
NCT02199197,Phase 2,25/06/2014,Actual,radium_223,A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer,Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer,0,2,0,0,2,,0,,0,192
NCT02215096,Phase 1,13/11/2014,Actual,enzalutamide,"A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination With Enzalutamide (Xtandi^TM ) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,,1,1,1,,,,,,34
NCT02225275,Phase 2,31/03/2016,Actual,lenalidomide,Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,0,0,1,0,,,0,,0,8
NCT02252172,Phase 3,16/02/2015,Actual,lenalidomide,"A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",0,10,56,2,46,,,24,62,2748
NCT02253316,Phase 2,20/01/2015,Actual,lenalidomide,"A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma","Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma",1,8,30,0,15,,1,,15,402
NCT02256111,Phase 2,13/05/2015,Actual,enzalutamide,EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer,EXTEND Exercise Trial,0,2,8,0,0,,0,,2,92
NCT02268175,Phase 2,31/10/2014,Actual,enzalutamide,A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy,Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,0,4,12,0,,,0,,4,130
NCT02272803,Phase 2,20/02/2015,Actual,lenalidomide,"A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan",Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan,0,164,0,0,,,0,,0,0
NCT02278185,Phase 2,11/11/2015,Actual,degarelix,"An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,,,,,0,,,,0,38
NCT02278185,Phase 2,11/11/2015,Actual,enzalutamide,"An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,,,,,0,,,,0,38
NCT02283749,Phase 2,30/09/2015,Actual,radium_223,BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases,BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases,0,1,0,0,,,0,,0,4
NCT02285062,Phase 3,21/01/2015,Actual,lenalidomide,"Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma",Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,,380,10,,62,,,10,32,1786
NCT02288247,Phase 3,01/12/2014,Actual,enzalutamide,"A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone",A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone,,,5,,,,,1,,681
NCT02294461,Phase 3,23/04/2014,Actual,enzalutamide,"Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy",An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants,0,790,0,0,,,0,,0,0
NCT02309515,Phase 2,11/06/2015,Actual,lenalidomide,"Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)","Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis",0,0,2,0,0,,0,,0,46
NCT02318784,Phase 2,15/07/2015,Actual,carfilzomib,Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers,Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers,0,0,8,0,,,0,,0,54
NCT02322320,Phase 3,31/03/2015,Actual,lenalidomide,"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)","Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)",,,,,36,,,,26,484
NCT02331368,Phase 2,30/06/2015,Actual,lenalidomide,Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma,Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,,,,,2,,,,1,26
NCT02335983,Phase 1,30/04/2015,Actual,carfilzomib,Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma,Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma,,8,28,2,14,,,14,8,354
NCT02335983,Phase 1,30/04/2015,Actual,lenalidomide,Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma,Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma,,8,28,2,14,,,14,8,354
NCT02346526,Phase 2,30/04/2015,Actual,radium_223,A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer,A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer,0,1,0,0,,,1,,2,18
NCT02353468,Phase 2,31/12/2009,Actual,lenalidomide,Phase II Study: Therapy With Bortezomib + Lenalidomide + Dexamethasone With Lenalidomide + Dexamethasone as Post Transplant Consolidation and Maintenance for Patients With Symptomatic Multiple Myeloma Following Autologous Transplantation,"Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant",0,0,3,0,,,0,,0,0
NCT02370888,Phase 1,16/05/2016,Actual,lenalidomide,"A Phase I Clinical Trial to Evaluate the Maximally Tolerated Dose (MTD), Dose Limiting Toxicities (DLTs) and Safety Profiles of Increasing Doses of Lenalidomide After Allo-HCT in AML and MDS Subjects With Minimal Residual Disease (MRD) Detected by the CD34+ Mixed Chimerism Analysis (UF-BMT-MRD-101)",Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease,,,,,0,,,,0,6
NCT02384382,Phase 2,30/11/2015,Actual,enzalutamide,"A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),0,0,2,0,0,,0,,1,43
NCT02399085,Phase 2,31/03/2016,Actual,lenalidomide,"A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)",A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,0,2,0,0,,,0,,7,72
NCT02407054,Phase 2,29/04/2015,Actual,enzalutamide,"A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,2,8,24,0,2,,0,,24,508
NCT02412878,Phase 3,09/09/2015,Actual,carfilzomib,"A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing",Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,,90,10,,14,,,26,46,1726
NCT02413489,Phase 2,02/09/2015,Actual,daratumumab,"An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma","An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",,12,,,6,,,4,20,102
NCT02430480,Phase 2,03/06/2015,Actual,enzalutamide,Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,0,2,6,0,1,,0,,5,64
NCT02441517,Phase 4,28/10/2015,Actual,enzalutamide,"A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting",A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment,0,1,0,0,1,,0,,0,6
NCT02457910,Phase 1/Phase 2,30/06/2015,Actual,enzalutamide,"A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,0,0,2,0,,,0,,2,56
NCT02474927,Phase 2,01/11/2015,Actual,carfilzomib,Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung),Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation,0,0,5,0,0,,0,,0,39
NCT02488759,Phase 1/Phase 2,13/10/2015,Actual,daratumumab,"Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors","An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",12,112,34,0,,,0,,48,950
NCT02489123,Phase 2,11/08/2015,Actual,enzalutamide,Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide,Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,0,0,1,0,0,,0,,0,15
NCT02491359,Phase 2,12/11/2015,Actual,carfilzomib,Carfilzomib for Treatment of Chronic Graft vs. Host Disease,Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease,0,0,3,1,3,,0,,0,33
NCT02491411,Not Applicable,30/09/2015,Actual,enzalutamide,A Pilot Study of Dexamethasone Therapy Prior to Rechallenge With Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial),Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel,0,0,1,0,0,,0,,4,3
NCT02492750,Phase 1,30/04/2016,Actual,lenalidomide,Phase I/II Double Blind Randomized Trial of Lenalidomide/Dexamethasone/Anakinra vs. Lenalidomide/Dexamethasone/Placebo in Patients With Early Stage Multiple Myeloma and High Plasma Cell Growth Rate,Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma,,,,,0,,,,0,28
NCT02500901,Phase 1,31/03/2016,Actual,enzalutamide,Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer With Enzalutamide and the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Niraparib: Hoosier Cancer Research Network GU14-202,Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),0,0,0,0,0,,0,,0,4
NCT02508636,Phase 2,22/12/2015,Actual,enzalutamide,Phase II Trial of Definitive Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer,Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer,0,1,2,0,0,,0,,2,17
NCT02522715,Phase 1/Phase 2,13/10/2015,Actual,enzalutamide,A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer,"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer",0,2,0,2,,,0,,6,62
NCT02528643,Phase 2,09/11/2015,Actual,enzalutamide,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma",A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma,0,154,16,2,6,,,2,0,480
NCT02538965,Phase 2,19/11/2015,Actual,lenalidomide,"A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects From 1 to = 18 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia.",A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia,,1,0,,,,,1,3,12
NCT02561273,Phase 1/Phase 2,31/10/2015,Actual,lenalidomide,"A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma",Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma,0,6,8,0,,,0,,8,64
NCT02579863,Phase 3,19/10/2015,Actual,lenalidomide,A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185).,Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),0,108,24,2,16,,2,,58,1030
NCT02589145,Phase 1/Phase 2,22/06/2016,Actual,lenalidomide,Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,0,2,0,0,6,,0,,2,22
NCT02597062,Phase 2,29/03/2016,Actual,carfilzomib,A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies,High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma,3,1,2,0,,,0,,1,68
NCT02605863,Phase 2,31/01/2016,Actual,enzalutamide,The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention,Enzalutamide for Bladder Cancer Chemoprevention,0,0,0,0,0,,0,,0,4
NCT02607228,Phase 1/Phase 2,08/12/2015,Actual,enzalutamide,"A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",,,6,,4,,,2,2,110
NCT02619682,Phase 2,30/12/2015,Actual,lenalidomide,Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma,Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma,1,0,2,0,1,,0,,0,56
NCT02631577,Phase 1/Phase 2,31/12/2015,Actual,lenalidomide,A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,,,,,2,,,,82,68
NCT02677896,Phase 3,09/03/2016,Actual,enzalutamide,"A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),0,310,32,0,166,,0,,204,3888
NCT02685267,Phase 2,29/02/2016,Actual,enzalutamide,A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide,Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer,0,0,8,0,,,0,,0,10
NCT02685826,Phase 1/Phase 2,25/04/2016,Actual,lenalidomide,"A Phase 1/2 Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (DEX)in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma,0,4,2,0,,,0,,12,94
NCT02711956,Phase 1/Phase 2,31/12/2016,Actual,enzalutamide,A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,0,8,8,0,14,,0,,8,262
NCT02720510,Phase 2,14/06/2016,Actual,lenalidomide,"A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",0,0,6,0,,,0,,0,6
NCT02728102,Phase 2,31/07/2016,Actual,lenalidomide,Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN 1401),Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401),2,8,30,0,22,,0,,26,472
NCT02733042,Phase 1/Phase 2,11/05/2016,Actual,lenalidomide,"A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",0,26,2,0,4,,,4,110,278
NCT02749903,Phase 2,30/06/2016,Actual,enzalutamide,A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers,Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,0,2,1,0,,,0,,4,39
NCT02758132,Phase 2,01/03/2016,Actual,enzalutamide,"Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",0,0,0,0,,,0,,2,0
NCT02799745,Phase 2,09/06/2016,Actual,enzalutamide,A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT),A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance,0,2,42,0,24,,0,,2,838
NCT02807454,Phase 2,07/07/2016,Actual,daratumumab,"A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma,,,,,0,,,,0,74
NCT02843074,Phase 2,21/09/2016,Actual,lenalidomide,"Phase 2 Study Assessing Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone in Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma","Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients",0,0,11,0,,,0,,0,41
NCT02867618,Phase 1/Phase 2,16/10/2016,Actual,carfilzomib,Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma,Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,0,2,3,0,2,,0,,2,19
NCT02875067,Phase 1/Phase 2,29/08/2016,Actual,lenalidomide,"A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",0,0,1,0,2,,2,,0,7
NCT02880228,Phase 2,16/09/2016,Actual,lenalidomide,"Phase 2 Trial of Pembrolizumab, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",0,0,0,0,0,,0,,2,20
NCT02898259,Phase 1/Phase 2,20/02/2017,Actual,lenalidomide,"A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma","Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma",0,0,2,0,0,,0,,0,74
NCT02917941,Phase 2,01/11/2016,Actual,lenalidomide,"A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma",A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma,,34,,,,,,,,34
NCT02927925,Phase 2,14/02/2017,Actual,daratumumab,"An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type","A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type",0,32,0,0,0,,0,,0,32
NCT02944565,Phase 2,22/02/2017,Actual,daratumumab,Daratumumab Infusion Acceleration,Daratumumab in Treating Patients With Multiple Myeloma,0,0,3,0,,,0,,1,24
NCT02951819,Phase 2,09/11/2016,Actual,daratumumab,"Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,0,4,22,0,10,,0,,20,344
NCT02954406,Phase 1,05/03/2017,Actual,lenalidomide,"A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",0,2,6,0,4,,0,,6,154
NCT03000452,Phase 2,14/03/2017,Actual,daratumumab,"MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab.",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM),0,0,1,,,,,,2,15
NCT03003520,Phase 2,28/02/2017,Actual,lenalidomide,"A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,0,0,0,0,0,,,2,0,182
NCT03011034,Phase 2,14/02/2017,Actual,daratumumab,A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,,,,,8,,,,4,56
NCT03016312,Phase 3,10/01/2017,Actual,enzalutamide,"A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen","A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",2,272,30,2,58,,4,,174,2542
NCT03019640,Phase 2,10/10/2017,Actual,lenalidomide,Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma,"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",,,,,3,,,,0,19
NCT03023423,Phase 1/Phase 2,23/12/2016,Actual,daratumumab,"A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer,0,0,0,0,2,,0,,62,332
NCT03029234,Phase 3,31/03/2017,Actual,carfilzomib,"An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China",Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma,,123,,,,,,,,
NCT03095118,Phase 2,07/09/2017,Actual,daratumumab,Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy,Daratumumab in Treatment of PGNMID and C3 GN,0,1,0,0,,,0,,0,11
NCT03098550,Phase 1/Phase 2,15/06/2017,Actual,daratumumab,Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors,"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",,,,,2,,,,120,88
NCT03150056,Phase 1,18/07/2017,Actual,enzalutamide,"A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer,,4,6,,,2,,,,134
NCT03158688,Phase 3,13/06/2017,Actual,carfilzomib,"A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.",,132,18,,16,,,50,42,1606
NCT03158688,Phase 3,13/06/2017,Actual,daratumumab,"A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.",,132,18,,16,,,50,42,1606
NCT03187262,Phase 2,27/11/2017,Actual,daratumumab,A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia,A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia,0,0,0,0,,,0,,0,13
NCT03201965,Phase 3,05/10/2017,Actual,daratumumab,"A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis","A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis",6,128,30,2,46,,2,,50,1400
NCT03256045,Phase 2,08/02/2018,Actual,carfilzomib,CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing,"Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",0,0,0,0,1,,0,,0,17
NCT03269552,Phase 2,18/12/2017,Actual,carfilzomib,A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma,Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma,0,0,0,0,0,,0,,0,8
NCT03275285,Phase 3,25/10/2017,Actual,carfilzomib,"Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients",0,100,18,0,,,6,,52,428
NCT03333746,Phase 2,21/03/2018,Actual,lenalidomide,Phase II Study of Lenalidomide in Combination With Nivolumab In Patients With Relapsed/Refractory Multiple Myeloma,Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,0,0,0,0,0,,0,,0,2
NCT03338790,Phase 2,19/12/2017,Actual,enzalutamide,"A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer","An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer",0,8,30,0,,,0,,50,496
NCT03357952,Phase 2/Phase 3,16/11/2017,Actual,daratumumab,"A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Subjects With Relapsed or Refractory Multiple Myeloma","A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma",0,0,2,0,0,,0,,0,38
NCT03411031,Phase 2,04/10/2018,Actual,lenalidomide,A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma,Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide,0,2,8,0,0,,0,,0,62
NCT03412565,Phase 2,26/04/2018,Actual,carfilzomib,A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,0,10,20,0,32,,0,,322,676
NCT03412565,Phase 2,26/04/2018,Actual,daratumumab,A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,0,10,20,0,32,,0,,322,676
NCT03412565,Phase 2,26/04/2018,Actual,lenalidomide,A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens,0,10,20,0,32,,0,,322,676
NCT03418324,Phase 2,05/03/2018,Actual,enzalutamide,"A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy",Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy,0,2,0,0,0,,0,,0,30
NCT03439293,Phase 2,13/03/2018,Actual,daratumumab,"A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)",A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM),0,0,3,0,1,,0,,10,108
NCT03481556,Phase 1/Phase 2,12/04/2018,Actual,daratumumab,An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma,Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM,0,0,4,0,2,,0,,16,202
NCT03512353,Phase 2,05/07/2018,Actual,carfilzomib,An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers,A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers,,,1,,0,,,,0,11
NCT03531827,Phase 2,26/03/2019,Actual,enzalutamide,"A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment","Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment",0,0,1,0,0,,0,,0,7
NCT03822078,Phase 1,30/09/2003,Actual,denosumab,"A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 162 Administered Subcutaneously to Japanese Postmenopausal Women","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women",,90,,,,,,,,
NCT03834519,Phase 3,02/05/2019,Actual,enzalutamide,"A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)",Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010),2,322,10,4,206,,2,,70,2556
NCT04052204,Phase 1/Phase 2,30/12/2019,Actual,enzalutamide,A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors,Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors,0,0,0,0,0,,0,,0,6
NCT04272775,Phase 1,05/06/2012,Actual,lenalidomide,A Phase 1 Study of MLN9708 in Japanese Patients With Relapsed and/or Refractory Multiple Myeloma,A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM),0,28,0,0,,,0,,0,0